|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2009-5-28
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
To our knowledge, to date, no prospective, randomized, clinical trial has compared standard doses of efavirenz- and nevirapine-based antiretroviral therapy among patients with concurrent human immunodeficiency virus type 1 (HIV-1) infection and tuberculosis (TB) who are receiving rifampicin.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
pubmed-author:BurapatarawongSunanthaS,
pubmed-author:LikanonsakulSiriratS,
pubmed-author:LueangniyomkulAroonA,
pubmed-author:MankatithamWirojW,
pubmed-author:ManosuthiWeerawatW,
pubmed-author:N2R Study Team,
pubmed-author:PrasithsirskulWisitW,
pubmed-author:PrommoolVilaiwanV,
pubmed-author:RuxrungthamKiatK,
pubmed-author:SungkanuparphSomnuekS,
pubmed-author:TantanathipPreechaP,
pubmed-author:ThawornwaUnchanaU,
pubmed-author:ThongyenSupedaS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1752-9
|
|
pubmed:dateRevised |
2009-10-16
|
|
pubmed:meshHeading |
pubmed-meshheading:19438397-Adult,
pubmed-meshheading:19438397-Anti-HIV Agents,
pubmed-meshheading:19438397-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:19438397-Benzoxazines,
pubmed-meshheading:19438397-CD4 Lymphocyte Count,
pubmed-meshheading:19438397-Drug Interactions,
pubmed-meshheading:19438397-Female,
pubmed-meshheading:19438397-HIV Infections,
pubmed-meshheading:19438397-HIV-1,
pubmed-meshheading:19438397-Humans,
pubmed-meshheading:19438397-Male,
pubmed-meshheading:19438397-Middle Aged,
pubmed-meshheading:19438397-Nevirapine,
pubmed-meshheading:19438397-Plasma,
pubmed-meshheading:19438397-Prospective Studies,
pubmed-meshheading:19438397-RNA, Viral,
pubmed-meshheading:19438397-Reverse Transcriptase Inhibitors,
pubmed-meshheading:19438397-Rifampin,
pubmed-meshheading:19438397-Treatment Outcome,
pubmed-meshheading:19438397-Tuberculosis,
pubmed-meshheading:19438397-Viral Load
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
|
|
pubmed:affiliation |
Dept. of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Tiwanon Rd., Nonthaburi 11000, Thailand. idweerawat@yahoo.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
